Complications and objective outcomes of uterine preserving surgeries for the repair of pelvic organ prolapse versus procedures removing the Uterus, a systematic review.


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 16 09 2021
revised: 15 10 2021
accepted: 17 10 2021
pubmed: 5 11 2021
medline: 15 12 2021
entrez: 4 11 2021
Statut: ppublish

Résumé

Several authors have recently compared the outcomes and complications of surgical procedures that preserve or remove the uterus in the treatment of pelvic organ prolapse (POP) and stress urinary incontinence (SUI). Following the publication of several high quality randomized control trials on this topic we performed a new systematic review and meta analysis of this data. We performed a systematic literature search in ClinicalTrials.gov, PubMed, Scopus, Ovid, EBSCO host, Science Direct, Web of Science, and Cochrane CENTRAL for randomized controlled and cohort trials of uterine sparing prolapse repair (hysteropexy) versus hysterectomy with suspension. A total of 1285 patients from 14 studies were included in our systematic review and meta-analysis. Uterine sparing procedures (hysteropexy) were comparable to hysterectomy with suspension for recurrence rates (RR = 0.908, 95% CI [0.385, 2.143]), reoperation rates (RR = 1.517, 95% CI [0.802, 2.868]), length of hospital stay, (SMD =  - 0.159 days, 95% CI [-0.375, 0.057]), voiding dysfunction (RR = 1.089, 95% CI [0.695, 1.706]), and intraoperative blood loss (SMD =  - 0.339, 95% CI [-0.631, 0.047]). However, hysteropexy had shorter operative time than hysterectomy with suspension (SMD =  - 1.191 h, 95% CI [-1.836, -0.545]), and fewer visceral injuries (RR = 0.421, 95% CI [0.244, 0.725]). We found no significant differences in the outcomes or major complications of uterine preserving surgical procedures versus those which include hysterectomy in the treatment of POP. Hysteropexy procedures may be associated with a shorter operative time and fewer visceral injuries. This is consistent with older analyses.

Sections du résumé

BACKGROUND BACKGROUND
Several authors have recently compared the outcomes and complications of surgical procedures that preserve or remove the uterus in the treatment of pelvic organ prolapse (POP) and stress urinary incontinence (SUI). Following the publication of several high quality randomized control trials on this topic we performed a new systematic review and meta analysis of this data.
METHODS METHODS
We performed a systematic literature search in ClinicalTrials.gov, PubMed, Scopus, Ovid, EBSCO host, Science Direct, Web of Science, and Cochrane CENTRAL for randomized controlled and cohort trials of uterine sparing prolapse repair (hysteropexy) versus hysterectomy with suspension. A total of 1285 patients from 14 studies were included in our systematic review and meta-analysis.
RESULTS RESULTS
Uterine sparing procedures (hysteropexy) were comparable to hysterectomy with suspension for recurrence rates (RR = 0.908, 95% CI [0.385, 2.143]), reoperation rates (RR = 1.517, 95% CI [0.802, 2.868]), length of hospital stay, (SMD =  - 0.159 days, 95% CI [-0.375, 0.057]), voiding dysfunction (RR = 1.089, 95% CI [0.695, 1.706]), and intraoperative blood loss (SMD =  - 0.339, 95% CI [-0.631, 0.047]). However, hysteropexy had shorter operative time than hysterectomy with suspension (SMD =  - 1.191 h, 95% CI [-1.836, -0.545]), and fewer visceral injuries (RR = 0.421, 95% CI [0.244, 0.725]).
CONCLUSION CONCLUSIONS
We found no significant differences in the outcomes or major complications of uterine preserving surgical procedures versus those which include hysterectomy in the treatment of POP. Hysteropexy procedures may be associated with a shorter operative time and fewer visceral injuries. This is consistent with older analyses.

Identifiants

pubmed: 34736035
pii: S0301-2115(21)00509-1
doi: 10.1016/j.ejogrb.2021.10.020
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-98

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ali Azadi (A)

Star Urogynecology, Advanced Pelvic Health Institute for Women, Peoria, AZ, USA; University of Arizona, College of Medicine, Department of Obstetrics and Gynecology, Phoenix, AZ, USA.

Greg Marchand (G)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA. Electronic address: gm@marchandinstitute.org.

Ahmed Taher Masoud (AT)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA; Faculty of Medicine, Fayoum University, Fayoum, Egypt.

Katelyn Sainz (K)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Malini Govindan (M)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Kelly Ware (K)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA; International University of the Health Sciences, Basseterre, Sain Kitts and Nevis.

Alexa King (A)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Stacy Ruther (S)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Giovanna Brazil (G)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Nicolas Calteux (N)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Hollie Ulibarri (H)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Julia Parise (J)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Amanda Arroyo (A)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Catherine Coriell (C)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Sydnee Goetz (S)

Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.

Donald R Ostergard (DR)

University of California, Irvine, Professor Emeritus, Department of Obstetrics and Gynecology, USA; UCLA School of Medicine, Professor-in-Residence, Division of Urogynecology, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH